

GLAXOSMITHKLINE PLC  
Form 6-K  
March 20, 2017

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending 20 March 2017

GlaxoSmithKline plc

(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes    No

GlaxoSmithKline plc  
Annual Report 2016 on Form 20-F

In accordance with Section 203.01 of the New York Stock Exchange Listed Company Manual, GlaxoSmithKline plc ("GSK") announces that on 17 March 2017 it filed with the Securities and Exchange Commission an Annual Report on Form 20-F that included audited financial statements for the year ended 31 December 2016. GSK's 2016 Annual Report on Form 20-F is available online at GSK's website at [www.gsk.com/corporatereporting](http://www.gsk.com/corporatereporting) and also online at [www.sec.gov](http://www.sec.gov).

Ordinary Shareholders may also elect to receive notification by email of the publication of financial reports by registering on [www.shareview.co.uk](http://www.shareview.co.uk).

A hard copy version of the GSK 2016 Annual Report, together with the Annual Summary and Notice of Annual General Meeting will be available on or about 30 March 2017.

Shareholders have the ability to receive, upon request, a hard copy version of GSK's complete audited financial statements for the year ended 31 December 2016, free of charge, by either:

(i) writing to Equiniti Limited, our registrars in the UK, at the following address: Equiniti Limited, Aspect House, Spencer Road, Lancing, West Sussex BN99 6DA, or by telephone on 0371 384 2991 (inside the UK) or +44 (0)121 415 7067 (outside the UK);

(ii) writing to The Bank of New York Mellon, our ADR depository in the US, at the following address: BNY Mellon, Shareholder Services, Receipts, PO Box 30170, College Station, Texas, TX 77842-3170, or by telephone on +1 877 353 1154 (US toll free) or +1 201 680 6825 (outside the US); or

(iii)

contacting the GSK Response Center in the USA at +1 888 825 5249 (US toll free).

Victoria Whyte  
Company Secretary  
17 March 2017

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Risk factors' in the company's Annual Report on Form 20-F for 2016.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: March 20, 2017

By: VICTORIA WHYTE

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc